Katherine Liddle Saxton, MD
Allergy & Immunology · Fayetteville, NCNPI 1972593432
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 591 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AstraZeneca at 24.9% of the total.
Across 591 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Sanofi$2K
- Takeda Pharmaceuticals U.S.A., Inc.$877
- Regeneron Healthcare Solutions, Inc.$640
- Pfizer$480
- plus $3K from 29 others
What the payments were for
- Food & beverage$11,09399%
- Education$1331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 111 | $2,800 |
| GSK | 125 | $1,717 |
| Sanofi | 84 | $1,540 |
| Takeda Pharmaceuticals U.S.A., Inc. | 53 | $877 |
| Regeneron Healthcare Solutions, Inc. | 29 | $640 |
| Pfizer | 27 | $480 |
| Grifols USA, LLC | 17 | $381 |
| Biocryst US Sales Co., LLC | 11 | $325 |
| Novartis | 16 | $312 |
| CSL Behring | 12 | $254 |
| Kaleo, Inc. | 13 | $212 |
| Amgen | 19 | $205 |
| Mylan Specialty L.p. | 4 | $167 |
| Genentech USA, Inc. | 6 | $166 |
| Pharming Healthcare, Inc. | 8 | $164 |
| Optinose US, Inc. | 8 | $128 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $102 |
| Alk-abello, Inc | 4 | $82 |
| Boehringer Ingelheim | 5 | $79 |
| Shire North American Group Inc | 5 | $78 |
| Teva Pharmaceuticals USA, Inc. | 5 | $69 |
| LEO Pharma Inc. | 4 | $66 |
| AbbVie | 3 | $66 |
| Aytu Biopharma, Inc. | 2 | $42 |
| Viatris Specialty LLC | 2 | $40 |
| Biocryst Pharmaceuticals, Inc. | 2 | $36 |
| Hospira, Inc. | 2 | $33 |
| Octapharma USA, Inc. | 2 | $31 |
| Ionis Pharmaceuticals, Inc. | 1 | $27 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Merck | 1 | $19 |
| USWM, LLC | 1 | $19 |
| Lilly USA, LLC | 1 | $16 |
| Verona Pharma, Inc. | 1 | $16 |
| Galderma Laboratories, L.p. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,226 in reported general payments places this provider in the 70th percentile of 140 allergy & immunology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 13 | $657,336 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 22 | $228,814 |
| NucalaMepolizumab | 44 | $165,014 |
| Dupixent SyringeDupilumab | 42 | $157,299 |
| TezspireTezepelumab-Ekko | 25 | $96,707 |
| Dupixent PenDupilumab | 21 | $81,016 |
| Fasenra PenBenralizumab | 13 | $73,231 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $46,638 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $16,560 |
| Spiriva RespimatTiotropium Bromide | 26 | $15,634 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $14,833 |
| SymbicortBudesonide/Formoterol Fumarate | 52 | $11,784 |
| Advair HfaFluticasone Propion/Salmeterol | 26 | $9,183 |
| Epinephrine | 33 | $5,949 |
| Arnuity ElliptaFluticasone Furoate | 22 | $5,590 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $877 | $657,33613 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,717 | $233,802159 claims |
| Grifols USA, LLCProlastin C | $381 | $228,81422 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $2,800 | $123,32495 claims |
| Boehringer IngelheimSpiriva Respimat | $79 | $15,63426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 140 allergy & immunology providers in North Carolina.
Other allergy & immunology in Fayetteville
- Maeve OconnorCharlotte$2.2M
- Joel HartmanWinston Salem$749K
- Cristine RadojicicDurham$558K
- Scott ComminsChapel Hill$555K
- William McCannAsheville$486K
- Aerik WilliamsSalisbury$298K
- Karen DunnRaleigh$258K
- Roopen PatelCharlotte$257K
- Jonathan RomeoRaleigh$230K
- John NorrisCharlotte$198K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.